Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Development of a Lab-on-a-Disk Platform with Digital Imaging for Identification and Counting of Parasite Eggs in Human and Animal Stool.

Sukas S, Van Dorst B, Kryj A, Lagatie O, De Malsche W, Stuyver LJ.

Micromachines (Basel). 2019 Dec 5;10(12). pii: E852. doi: 10.3390/mi10120852.

2.

Assessment of multiplex Onchocerca volvulus peptide ELISA in non-endemic tropical regions.

Lagatie O, Granjon E, Odiere MR, Zrein M, Stuyver LJ.

Parasit Vectors. 2019 Nov 29;12(1):570. doi: 10.1186/s13071-019-3824-x.

3.

Performance evaluation of 3 serodiagnostic peptide epitopes and the derived multi-epitope peptide OvNMP-48 for detection of Onchocerca volvulus infection.

Lagatie O, Verheyen A, Nijs E, Batsa Debrah L, Debrah YA, Stuyver LJ.

Parasitol Res. 2019 Jul;118(7):2263-2270. doi: 10.1007/s00436-019-06345-3. Epub 2019 May 14.

4.

Patent infections with soil-transmitted helminths and Schistosoma mansoni are not associated with increased prevalence of antibodies to the Onchocerca volvulus peptide epitopes OvMP-1 and OvMP-23.

Vlaminck J, Lagatie O, Verheyen A, Dana D, Van Dorst B, Mekonnen Z, Levecke B, Stuyver LJ.

Parasit Vectors. 2019 Jan 28;12(1):63. doi: 10.1186/s13071-019-3308-z.

5.

Linear epitopes in Onchocerca volvulus vaccine candidate proteins and excretory-secretory proteins.

Lagatie O, Verheyen A, Van Dorst B, Batsa Debrah L, Debrah A, Stuyver LJ.

Parasite Immunol. 2018 Nov;40(11):e12587. doi: 10.1111/pim.12587. Epub 2018 Oct 8.

6.

Evaluation of the Diagnostic Performance of Onchocerca volvulus Linear Epitopes in a Peptide Enzyme-Linked Immunosorbent Assay.

Lagatie O, Verheyen A, Nijs E, Van Dorst B, Batsa Debrah L, Debrah A, Supali T, Sartono E, Stuyver LJ.

Am J Trop Med Hyg. 2018 Mar;98(3):779-785. doi: 10.4269/ajtmh.17-0756. Epub 2018 Jan 4.

7.

2-methyl butyramide, a previously identified urine biomarker for Ascaris lumbricoides, is not present in infected Indonesian individuals.

Lagatie O, Njumbe Ediage E, Pikkemaat JA, Djuardi Y, Stuyver LJ.

Parasit Vectors. 2017 Dec 29;10(1):629. doi: 10.1186/s13071-017-2600-z.

8.

Identification of three immunodominant motifs with atypical isotype profile scattered over the Onchocerca volvulus proteome.

Lagatie O, Van Dorst B, Stuyver LJ.

PLoS Negl Trop Dis. 2017 Jan 26;11(1):e0005330. doi: 10.1371/journal.pntd.0005330. eCollection 2017 Jan.

9.

Plasma-derived parasitic microRNAs have insufficient concentrations to be used as diagnostic biomarker for detection of Onchocerca volvulus infection or treatment monitoring using LNA-based RT-qPCR.

Lagatie O, Batsa Debrah L, Debrah A, Stuyver LJ.

Parasitol Res. 2017 Mar;116(3):1013-1022. doi: 10.1007/s00436-017-5382-5. Epub 2017 Jan 22.

10.

An isothermal DNA amplification method for detection of Onchocerca volvulus infection in skin biopsies.

Lagatie O, Merino M, Batsa Debrah L, Debrah AY, Stuyver LJ.

Parasit Vectors. 2016 Dec 1;9(1):624.

11.

Evaluation of the diagnostic potential of urinary N-Acetyltyramine-O,β-glucuronide (NATOG) as diagnostic biomarker for Onchocerca volvulus infection.

Lagatie O, Njumbe Ediage E, Batsa Debrah L, Diels L, Nolten C, Vinken P, Debrah A, Dillen L, Silber S, Stuyver LJ.

Parasit Vectors. 2016 May 23;9(1):302. doi: 10.1186/s13071-016-1582-6.

12.

Integration of an optical CMOS sensor with a microfluidic channel allows a sensitive readout for biological assays in point-of-care tests.

Van Dorst B, Brivio M, Van Der Sar E, Blom M, Reuvekamp S, Tanzi S, Groenhuis R, Adojutelegan A, Lous EJ, Frederix F, Stuyver LJ.

Biosens Bioelectron. 2016 Apr 15;78:126-131. doi: 10.1016/j.bios.2015.11.027. Epub 2015 Nov 11.

PMID:
26599482
13.

Characterization of Rabbit Antibodies Against the Immunogenic JC Polyomavirus Peptide JCPyV_VP2_167-15mer.

Lagatie O, Tritsmans L, Stuyver LJ.

Viral Immunol. 2015 Sep;28(7):405-9. doi: 10.1089/vim.2015.0010. Epub 2015 Jun 15.

PMID:
26075335
14.

Sampling variability between two mid-turbinate swabs of the same patient has implications for influenza viral load monitoring.

Van Wesenbeeck L, Meeuws H, D'Haese D, Ispas G, Houspie L, Van Ranst M, Stuyver LJ.

Virol J. 2014 Dec 24;11:233. doi: 10.1186/s12985-014-0233-9.

15.

JC virus quasispecies analysis reveals a complex viral population underlying progressive multifocal leukoencephalopathy and supports viral dissemination via the hematogenous route.

Van Loy T, Thys K, Ryschkewitsch C, Lagatie O, Monaco MC, Major EO, Tritsmans L, Stuyver LJ.

J Virol. 2015 Jan 15;89(2):1340-7. doi: 10.1128/JVI.02565-14. Epub 2014 Nov 12.

16.

Antibodies reacting with JCPyV_VP2 _167-15mer as a novel serological marker for JC polyomavirus infection.

Lagatie O, Van Loy T, Tritsmans L, Stuyver LJ.

Virol J. 2014 Oct 1;11:174. doi: 10.1186/1743-422X-11-174.

17.

Viral miRNAs in plasma and urine divulge JC polyomavirus infection.

Lagatie O, Van Loy T, Tritsmans L, Stuyver LJ.

Virol J. 2014 Sep 2;11:158. doi: 10.1186/1743-422X-11-158.

18.

Integration of clinical point-of-care requirements in a DNA microarray genotyping test.

Van Dorst B, Cremers A, Jans K, Van Domburg T, Steegen K, Huang C, Dorrer C, Lagae L, Ferwerda G, Stuyver LJ.

Biosens Bioelectron. 2014 Nov 15;61:605-11. doi: 10.1016/j.bios.2014.05.071. Epub 2014 Jun 11.

PMID:
24967749
19.

Circulating human microRNAs are not linked to JC polyomavirus serology or urinary viral load in healthy subjects.

Lagatie O, Van Loy T, Tritsmans L, Stuyver LJ.

Virol J. 2014 Mar 3;11:41. doi: 10.1186/1743-422X-11-41.

20.

Evaluation of an affordable HIV-1 virological failure assay and antiretroviral drug resistance genotyping protocol.

Bronze M, Aitken SC, Wallis CL, Steegen K, Stuyver LJ, de Wit TF, Stevens W.

J Virol Methods. 2013 Dec;194(1-2):300-7. doi: 10.1016/j.jviromet.2013.08.015. Epub 2013 Aug 28.

PMID:
23994150
21.

The miRNA world of polyomaviruses.

Lagatie O, Tritsmans L, Stuyver LJ.

Virol J. 2013 Aug 28;10:268. doi: 10.1186/1743-422X-10-268. Review.

22.

Quasispecies analysis of JC virus DNA present in urine of healthy subjects.

Van Loy T, Thys K, Tritsmans L, Stuyver LJ.

PLoS One. 2013 Aug 15;8(8):e70950. doi: 10.1371/journal.pone.0070950. eCollection 2013.

23.

Sensitive assessment of the virologic outcomes of stopping and restarting non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.

Geretti AM, Fox Z, Johnson JA, Booth C, Lipscomb J, Stuyver LJ, Tachedjian G, Baxter J, Touloumi G, Lehmann C, Owen A, Phillips A; INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group.

PLoS One. 2013 Jul 18;8(7):e69266. doi: 10.1371/journal.pone.0069266. Print 2013.

24.

Amplification and sequencing of the hepatitis C virus NS3/4A protease and the NS5B polymerase regions for genotypic resistance detection of clinical isolates of subtypes 1a and 1b.

Koletzki D, Pattery T, Fevery B, Vanhooren L, Stuyver LJ.

Methods Mol Biol. 2013;1030:137-49. doi: 10.1007/978-1-62703-484-5_12.

PMID:
23821266
25.

An antibody response to human polyomavirus 15-mer peptides is highly abundant in healthy human subjects.

Stuyver LJ, Verbeke T, Van Loy T, Van Gulck E, Tritsmans L.

Virol J. 2013 Jun 12;10:192. doi: 10.1186/1743-422X-10-192.

26.

HIV-1 phenotypic reverse transcriptase inhibitor drug resistance test interpretation is not dependent on the subtype of the virus backbone.

Bronze M, Steegen K, Wallis CL, De Wolf H, Papathanasopoulos MA, Van Houtte M, Stevens WS, de Wit TR, Stuyver LJ; ART-A Consortium.

PLoS One. 2012;7(4):e34708. doi: 10.1371/journal.pone.0034708. Epub 2012 Apr 9.

27.

Ultra-deep sequencing of HIV-1 reverse transcriptase before start of an NNRTI-based regimen in treatment-naive patients.

Messiaen P, Verhofstede C, Vandenbroucke I, Dinakis S, Van Eygen V, Thys K, Winters B, Aerssens J, Vogelaers D, Stuyver LJ, Vandekerckhove L.

Virology. 2012 Apr 25;426(1):7-11. doi: 10.1016/j.virol.2012.01.002. Epub 2012 Feb 4.

28.

A synthetic HIV-1 subtype C backbone generates comparable PR and RT resistance profiles to a subtype B backbone in a recombinant virus assay.

Nauwelaers D, Van Houtte M, Winters B, Steegen K, Van Baelen K, Chi E, Zhou M, Steiner D, Bonesteel R, Aston C, Stuyver LJ.

PLoS One. 2011;6(5):e19643. doi: 10.1371/journal.pone.0019643. Epub 2011 May 24.

29.

HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.

Svicher V, Balestra E, Cento V, Sarmati L, Dori L, Vandenbroucke I, D'Arrigo R, Buonomini AR, Van Marck H, Surdo M, Saccomandi P, Mostmans W, Aerssens J, Aquaro S, Stuyver LJ, Andreoni M, Ceccherini-Silberstein F, Perno CF.

Antiviral Res. 2011 Apr;90(1):42-53. doi: 10.1016/j.antiviral.2011.02.005. Epub 2011 Feb 22.

PMID:
21349294
30.

Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment.

Vandekerckhove L, Verhofstede C, Demecheleer E, De Wit S, Florence E, Fransen K, Moutschen M, Mostmans W, Kabeya K, Mackie N, Plum J, Vaira D, Van Baelen K, Vandenbroucke I, Van Eygen V, Van Marck H, Vogelaers D, Geretti AM, Stuyver LJ.

J Antimicrob Chemother. 2011 Feb;66(2):265-72. doi: 10.1093/jac/dkq458. Epub 2010 Dec 31.

31.

Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treated clinical isolates.

Van Wesenbeeck L, Rondelez E, Feyaerts M, Verheyen A, Van der Borght K, Smits V, Cleybergh C, De Wolf H, Van Baelen K, Stuyver LJ.

Antimicrob Agents Chemother. 2011 Jan;55(1):321-5. doi: 10.1128/AAC.01733-09. Epub 2010 Oct 18.

32.

A comparative analysis of HIV drug resistance interpretation based on short reverse transcriptase sequences versus full sequences.

Steegen K, Bronze M, Van Craenenbroeck E, Winters B, Van der Borght K, Wallis CL, Stevens W, Rinke de Wit TF, Stuyver LJ; ART-A consortium.

AIDS Res Ther. 2010 Oct 15;7:38. doi: 10.1186/1742-6405-7-38.

33.

HIV-1 V3 envelope deep sequencing for clinical plasma specimens failing in phenotypic tropism assays.

Vandenbroucke I, Van Marck H, Mostmans W, Van Eygen V, Rondelez E, Thys K, Van Baelen K, Fransen K, Vaira D, Kabeya K, De Wit S, Florence E, Moutschen M, Vandekerckhove L, Verhofstede C, Stuyver LJ.

AIDS Res Ther. 2010 Feb 15;7:4. doi: 10.1186/1742-6405-7-4.

34.

Mutation Q95K enhances N155H-mediated integrase inhibitor resistance and improves viral replication capacity.

Fun A, Van Baelen K, van Lelyveld SF, Schipper PJ, Stuyver LJ, Wensing AM, Nijhuis M.

J Antimicrob Chemother. 2010 Nov;65(11):2300-4. doi: 10.1093/jac/dkq319. Epub 2010 Aug 24.

PMID:
20736234
35.

Development and evaluation of an automated hepatitis C virus NS5B sequence-based subtyping assay.

Koletzki D, Dumont S, Vermeiren H, Fevery B, De Smet P, Stuyver LJ.

Clin Chem Lab Med. 2010 Aug;48(8):1095-102. doi: 10.1515/CCLM.2010.236.

PMID:
20578969
36.

Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.

Ceccherini-Silberstein F, Van Baelen K, Armenia D, Trignetti M, Rondelez E, Fabeni L, Scopelliti F, Pollicita M, Van Wesenbeeck L, Van Eygen V, Dori L, Sarmati L, Aquaro S, Palamara G, Andreoni M, Stuyver LJ, Perno CF.

Antimicrob Agents Chemother. 2010 Sep;54(9):3938-48. doi: 10.1128/AAC.01720-09. Epub 2010 May 17.

37.

The HIV-1 integrase mutations Y143C/R are an alternative pathway for resistance to Raltegravir and impact the enzyme functions.

Reigadas S, Anies G, Masquelier B, Calmels C, Stuyver LJ, Parissi V, Fleury H, Andreola ML.

PLoS One. 2010 Apr 26;5(4):e10311. doi: 10.1371/journal.pone.0010311.

38.

A combined genotypic and phenotypic human immunodeficiency virus type 1 recombinant virus assay for the reverse transcriptase and integrase genes.

Van Baelen K, Rondelez E, Van Eygen V, Ariën K, Clynhens M, Van den Zegel P, Winters B, Stuyver LJ.

J Virol Methods. 2009 Nov;161(2):231-9. doi: 10.1016/j.jviromet.2009.06.015. Epub 2009 Jun 25.

PMID:
19559730
39.

Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1.

Van Baelen K, Salzwedel K, Rondelez E, Van Eygen V, De Vos S, Verheyen A, Steegen K, Verlinden Y, Allaway GP, Stuyver LJ.

Antimicrob Agents Chemother. 2009 May;53(5):2185-8. doi: 10.1128/AAC.01650-08. Epub 2009 Feb 17.

40.

Full genome sequence of three isolates of hepatitis C virus subtype 4b from Portugal.

Koletzki D, Dumont S, Vermeiren H, Peixe P, Nina J, Camacho RJ, Stuyver LJ.

Arch Virol. 2009;154(1):127-32. doi: 10.1007/s00705-008-0270-z. Epub 2008 Dec 3. No abstract available.

PMID:
19050819
41.

Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility.

Van Baelen K, Van Eygen V, Rondelez E, Stuyver LJ.

AIDS. 2008 Sep 12;22(14):1877-80. doi: 10.1097/QAD.0b013e32830f9703.

PMID:
18753927
42.

Minor Variant Detection at Different Template Concentrations in HIV-1 Phenotypic and Genotypic Tropism Testing.

Vandenbroucke I, Eygen VV, Rondelez E, Vermeiren H, Baelen KV, Stuyver LJ.

Open Virol J. 2008;2:8-14. doi: 10.2174/1874357900802010008. Epub 2008 Mar 18.

43.

HIV-1 coreceptor usage determination in clinical isolates using clonal and population-based genotypic and phenotypic assays.

Van Baelen K, Vandenbroucke I, Rondelez E, Van Eygen V, Vermeiren H, Stuyver LJ.

J Virol Methods. 2007 Dec;146(1-2):61-73. Epub 2007 Jul 19.

PMID:
17640743
44.

Mechanism of activation of beta-D-2'-deoxy-2'-fluoro-2'-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase.

Murakami E, Bao H, Ramesh M, McBrayer TR, Whitaker T, Micolochick Steuer HM, Schinazi RF, Stuyver LJ, Obikhod A, Otto MJ, Furman PA.

Antimicrob Agents Chemother. 2007 Feb;51(2):503-9. Epub 2006 Nov 13.

45.

Inhibition of hepatitis C replicon RNA synthesis by beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine: a specific inhibitor of hepatitis C virus replication.

Stuyver LJ, McBrayer TR, Tharnish PM, Clark J, Hollecker L, Lostia S, Nachman T, Grier J, Bennett MA, Xie MY, Schinazi RF, Morrey JD, Julander JL, Furman PA, Otto MJ.

Antivir Chem Chemother. 2006;17(2):79-87.

PMID:
17042329
46.

Synthesis and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methyl purine nucleosides as inhibitors of hepatitis C virus RNA replication.

Clark JL, Mason JC, Hollecker L, Stuyver LJ, Tharnish PM, McBrayer TR, Otto MJ, Furman PA, Schinazi RF, Watanabe KA.

Bioorg Med Chem Lett. 2006 Mar 15;16(6):1712-5. Epub 2005 Dec 20.

PMID:
16368235
47.

N4-hydroxycytosine dioxolane nucleosides and their activity against hepatitis B virus.

Du J, Hollecker L, Shi J, Chun BK, Watanabe KA, Raymond FS, Nachman TY, Lostia S, Stuyver LJ, Otto MJ.

Nucleosides Nucleotides Nucleic Acids. 2005;24(8):1209-14.

PMID:
16270663
48.

Synthesis and anti-hepatitis C virus activity of nucleoside derivatives of N3, 5'-anhydro-4-(beta-D-ribofuranosyl)-8-aza-purin-2-ones.

Hassan AE, Wang P, McBrayer TR, Tharnish PM, Stuyver LJ, Schinazi RF, Otto MJ, Watanabe KA.

Nucleosides Nucleotides Nucleic Acids. 2005;24(5-7):961-4.

PMID:
16248072
49.

Synthesis of N3,5'-cyclo-4-(beta-D-ribofuranosyl)-vic-triazolo[4,5-b]pyridin-5-one and its 3'-deoxysugar analogue as potential anti-hepatitis C virus agents.

Wang P, Hollecker L, Pankiewicz KW, Patterson SE, Whitaker T, McBrayer TR, Tharnish PM, Stuyver LJ, Schinazi RF, Otto MJ, Watanabe KA.

Nucleosides Nucleotides Nucleic Acids. 2005;24(5-7):957-60.

PMID:
16248071
50.

Synthesis and in vitro anti-HCV activity of beta-D- and 1-2'-deoxy-2'-fluororibonucleosides.

Shi J, Du J, Ma T, Pankiewicz KW, Patterson SE, Hassan AE, Tharnish PM, McBrayer TR, Lostia S, Stuyver LJ, Watanabe KA, Chu CK, Schinazi RF, Otto MJ.

Nucleosides Nucleotides Nucleic Acids. 2005;24(5-7):875-9.

PMID:
16248053

Supplemental Content

Loading ...
Support Center